文献速递血栓与止血

胰腺癌患者全血凝血酶生成改变及血小板高反应性

Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer.
PubMed 文献 · J Thromb Haemost · 2024-01-17

本研究比较了18例胰腺导管腺癌(PDAC)患者与18例年龄性别匹配的健康对照者的血细胞依赖性凝血,发现患者全血凝血酶生成潜力增加、滞后时间延长,且血小板颗粒释放时间缩短;全血滞后时间缩短和血小板颗粒释放能力增加与血栓栓塞事件相关。

要点

  • PDAC患者全血凝血酶生成潜力增加而血浆中无差异,提示血细胞促凝效应。
  • PDAC患者血小板高反应,颗粒释放达峰时间缩短。
  • 全血滞后时间缩短和血小板颗粒释放能力增加与血栓栓塞事件相关。

核心结论

  • PDAC患者较对照者全血凝血酶生成增强且延迟,全血滞后时间缩短和血小板颗粒释放能力增加与血栓栓塞事件发生相关,血小板似乎是血栓形成的关键因素,全血止血检测可能改善PDAC患者的血栓风险估计。

研究设计与样本

  • 研究比较了18例PDAC患者与18例年龄和性别匹配的健康对照者,检测全血和血浆凝血酶生成及全血血小板颗粒释放能力,并随访6个月观察血栓栓塞事件。

主要发现

  • 患者全血内源性凝血酶潜力较对照者增加,血浆中未观察到此差异,提示血细胞的促凝效应。
  • 患者全血和血浆滞后时间均较对照者延长。
  • 患者血小板高反应,颗粒释放达峰时间缩短。
  • 18例PDAC患者中4例发生静脉血栓栓塞(22%),1例发生动脉血栓形成(6%)。
  • 全血滞后时间缩短(而非血浆)和血小板颗粒释放能力增加与血栓栓塞事件相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thromboembolic disease is a major complication in patients with pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC often have altered blood cell counts, which are associated with venous thromboembolism (VTE) development. The high thrombotic risk in patients with PDAC may be partially caused by procoagulant blood cells. OBJECTIVES: The aim of this study was to compare blood cell-dependent coagulation between patients with PDAC (n = 18) and healthy controls matched for age and sex (n = 18). METHODS: Thrombin generation (TG) was measured in whole blood (WB) and plasma. The capacity of platelets to release granules (PGRCs) was measured in WB. We explored the occurrence of thromboembolic events in patients with PDAC during a 6-month follow-up. RESULTS: Patients showed an increased endogenous thrombin potential in WB compared with controls. This difference was not observed in plasma, indicating a procoagulant effect of blood cells. Both in WB and plasma, the lag time was prolonged in patients compared with controls. Patients had hyperresponsive platelets, with a shorter time to peak granule release. Of the 18 patients with PDAC, 4 developed a venous thromboembolism (22%) and 1 developed an arterial thrombosis (6%). A shorter lag time in WB, but not in plasma, and an increased PGRC were associated with thromboembolic events. CONCLUSION: Patients with PDAC have an increased and delayed WB TG coagulation profile compared with controls. A shorter lag time in WB TG and increased PGRC are associated with the incidence of thromboembolic events. Platelets appear to be key players in thrombosis development. Measuring hemostasis in WB could improve thrombosis risk estimation in patients with PDAC.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Willems RAL, Konings J, Huskens D, et al. Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer. J Thromb Haemost. 2024. PMID: 38237861. doi:10.1016/j.jtha.2023.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。